Put CV Risks With Testosterone in Perspective
August 2023
New evidence will help clarify CV risk of testosterone replacement in men with hypogonadism.
Testosterone product labels caution about possible increased risk of heart attack and stroke...but this is based on small and observational trials with conflicting data.
Now a new study suggests transdermal 1.62% testosterone gel daily for about 22 months does not increase risk of CV death, heart attack, or stroke more than placebo.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive